Table 1.
Combined RTOG 9202 and RTOG 9902 Pretreatment Characteristics
| Gleason Score |
|||||
|---|---|---|---|---|---|
| Characteristic | 2-6 (n=524) n (%) |
7 (n=574) n (%) |
8 (No GP5) (n=209) n (%) |
8 (GP5), 9-10 (n=363) n (%) |
Total (n=1670) n (%) |
| Age | |||||
| Mean | 69.5 | 68.6 | 67.9 | 68.1 | 68.7 |
| Standard Deviation | 6.5 | 6.8 | 7.5 | 7.5 | 7.0 |
| Min - Max | 44 - 86 | 44 - 87 | 43 - 88 | 42 - 88 | 42 - 88 |
| p-value* | 0.0074 | ||||
| PSA, ng/mL - Continuous | |||||
| Mean | 26.6 | 35.6 | 28.2 | 27.6 | 30.1 |
| Standard Deviation | 26.9 | 31.0 | 29.3 | 26.7 | 28.9 |
| Min - Max | 0.4 - 180.3 | 0.2 - 250 | 1.2 - 172.7 | 0.123 - 152 | 0.123 - 250 |
| p-value* | <0.0001 | ||||
| PSA - Dichotomized | |||||
| ≤ 30 ng/mL | 383 (73.1%) | 332 (57.8%) | 146 (69.9%) | 251 (69.1%) | 1112 (66.6%) |
| > 30 ng/mL | 141 (26.9%) | 242 (42.2%) | 63 (30.1%) | 112 (30.9%) | 558 (33.4%) |
| p-value** | >0.0001 | ||||
| KPS/Zubrod | |||||
| Zubrod 0, KPS 90-100 | 481 (91.8%) | 533 (92.9%) | 184 (88.0%) | 334 (92.0%) | 1532 (91.7%) |
| Zubrod 1, KPS 70-80 | 43 (8.2%) | 41 (7.1%) | 25 (12.0%) | 29 (8.0%) | 138 (8.3%) |
| p-value** | 0.1902 | ||||
| Clinical T-Stage | |||||
| T1 | 0 (0.0%) | 33 (5.7%) | 7 (3.3%) | 10 (2.8%) | 50 (3.0%) |
| T2 | 288 (55.0%) | 236 (41.1%) | 113 (54.1%) | 161 (44.4%) | 798 (47.8%) |
| T3 | 223 (42.6%) | 285 (49.7%) | 82 (39.2%) | 174 (47.9%) | 764 (45.7%) |
| T4 | 13 (2.5%) | 20 (3.5%) | 7 (3.3%) | 18 (5.0%) | 58 (3.5%) |
| p-value** | <0.0001 | ||||
| Study | |||||
| 9202 | 524 (100.0%) | 449 (78.2%) | 101 (48.3%) | 218 (60.1%) | 1292 (77.4%) |
| 9902 | 0 (0.0%) | 125 (21.8%) | 108 (51.7%) | 145 (39.9%) | 378 (22.6%) |
| p-value** | <0.0001 | ||||